Classification of Covid19 Vaccine-Related Tweets Using Deep Learning

Vaccines save thousands of lives each year. Producing a safe and effective coronavirus vaccine is a huge step forward in global efforts to end the COVID-19 pandemic. COVID-19 vaccines are safe, and getting vaccinated will help protect people against developing severe COVID-19 disease and dying from it. Side effects usually occur within the first few days of getting a vaccine. Since the first mass vaccination program started in early December 2020, hundreds of millions of vaccine doses have been administered. Like any vaccine, COVID-19 vaccines can cause side effects, most of which are mild or moderate and go away within a few days on their own. As shown in the results of clinical trials, more serious or long-lasting side effects are possible. Vaccines are continually monitored to detect adverse effects. Reported side effects of COVID-19 vaccines have mostly been mild to moderate and have lasted no longer than a few days.According to the Centers for Disease Control and Prevention (CDC) Trusted Source and World Health Organization (WHO) Trusted Source, common side effects of a COVID-19 vaccine include fever, fatigue, headaches, body aches, chills, and nausea. A person might also experience side effects around the injection site, which is usually the upper arm. These might include swelling, pain, redness, and itchy rash, and other mild forms of irritation. The chances of any of these side effects following vaccination differ according to the specific COVID-19 vaccine. Pfizer-BioNTech, Moderna, and Sputnik V vaccines are more effective in the human population than other vaccines. Novavax vaccine has fewer side effects than Pfizer-BioNTech and Moderna.

In ongoing efforts to vaccinate communities against COVID-19, pharmacists must address fear and misinformation

Looking back: Pharmacists share COVID-19 vaccination lessons one year later

Background and AimThe COVID‐19 pandemic has significantly impacted human lives across the world. In a country like India, with the second highest population in the world, impact of COVID‐19 has been diverse and multidimensional. Under such circumstances, vaccination against COVID‐19 infection is claimed to be one of the major solutions to contain the pandemic. Understanding of Knowledge, Attitude and Practice (KAP) measures are essential prerequisites to design suitable intervention programs. This paper examines the different KAP factors in Indians towards their decision of vaccine uptake.MethodAn online questionnaire was administered to Indian respondents. (Pilot study: n = 100, Main study: n = 221) to assess their existing knowledge on COVID‐19 infections and vaccination, attitude and intentions towards COVID‐19 vaccines and their decision towards COVID‐19 vaccine uptake.ResultThe findings highlighted that existing knowledge on COVID‐19 infections and vaccination directly impacted their attitude and intention towards vaccination. The attitude and intention towards COVID‐19 vaccines directly impacted their practice of undergoing COVID‐19 vaccination. Further, there was a statistically significant and considerably large indirect effect of existing knowledge on COVID‐19 infections and vaccination on the practice of undergoing COVID‐19 vaccination through attitude and intention towards the vaccine. There was no direct effect of Knowledge (existing knowledge on COVID‐19 infections and vaccination) on Practice (decision to undergo COVID‐19 vaccination). Therefore, Attitude and intention towards COVID‐19 vaccine is the primary mediator between Knowledge (existing knowledge on COVID‐19 infections and vaccination) and Practice (decision to undergo COVID‐19 vaccination).ConclusionParticipants decision towards COVID‐19 vaccination decisions are strongly related to their attitude and intentions that confirms the strong role of attitude towards success of COVID‐19 vaccination programme. Therefore, ‘person‐centric’ attitude based positive intervention strategies that links their prior knowledge on COVID‐19 infections and vaccination must be designed for greater vaccine acceptance amongst Indians.

BackgroundPatients with autoimmune rheumatic disease (AIRD) are at risk of severe COVID-19 infection and vaccine has been demonstrated to be able to reduce the severity of infection. Malaysia has a...

Vaccine acceptance in the general public is essential in controlling the coronavirus disease 2019 (COVID-19) pandemic. The study aimed to assess the COVID-19 vaccine hesitancy in the adult population of Mongolia, and determine the associated factors. A total of 2875 individuals from urban and rural areas were recruited, and completed an online survey. Older age, urban residence, previous vaccination, high education, good knowledge of side effects, and a personal view of the importance of vaccines were associated with vaccine acceptability, whereas gender and religion were not. Receiving COVID-19 vaccine information from official government pages was related to a higher acceptance rate. Reliance on social media as a source of COVID-19 vaccine information was associated with high level of vaccine hesitancy. The side effects and the type of the COVID-19 vaccine were a major reason for hesitation. Countering false information regarding COVID-19 vaccines on social media, and promoting vaccine importance on general news websites is necessary. Moreover, providing clear and direct educational materials through official communication channels on the safety and efficacy of COVID-19 vaccines alongside information on COVID-19 symptoms, vaccine side effects, and location of vaccine administration centers among the younger populations, rural residents, and those with lower education is needed.

COVID-19 vaccines, perceptions and trust amongst vaccine refusers: A qualitative thematic analysis study

PurposeThis study examined the Bangladeshi university students’ intention to take coronavirus disease 2019 (COVID-19) vaccines by assessing the Health Belief Model and Theory of Planned Behavior.Materials and MethodsUniversity students were queried on their intention to take COVID-19 vaccines. The sample used in this study (n=310) was obtained through an online survey among university students (age, 18–25 years old) from August 7 to September 18, 2021.ResultsAlthough over 90% of respondents showed their willingness to take the COVID-19 vaccine, around 37.3% of respondents still desired to wait and see to take the vaccine. The most frequently cited reasons for vaccines hesitancy were concerns over side effects (62.4%). There is still an unmet need for adequate information on COVID-19 vaccines (81.4%). Results of the binary logistic regression model showed that students from private universities (odds ratio [OR], 0.19; 95% confidence interval [CI], 0.04–0.97), respondents who concerned about the vaccine safety (OR, 0.07; 95% CI, 0.01–0.44) and side effects of vaccine (OR, 0.21; 95% CI, 0.05–0.89) were less willing to take COVID-19 vaccine. On the other hand, desire to wait to take COVID-19 vaccines was associated with marital status (OR, 7.76; 95% CI, 1.50–40.27); COVID-19 preventive behavior, including use of facemask (OR, 0.25; 95% CI, 0.09–0.70) and maintain social distance (OR,1.75; 95% CI, 1.00–3.07); COVID-19 infection (OR, 0.50; 95% CI, 0.26–0.99); provide more information on vaccines (OR, 2.32; 95% CI, 1.06–5.09); the perceived side effects (OR, 2.82; 95% CI, 1.54–5.17); and effectiveness of COVID-19 vaccines (OR, 2.41; 95% CI, 1.16–5.01).ConclusionPublic health managers should provide adequate information on COVID-19 vaccines to address the concerns about the safety and side effects of the vaccines.

ObjectivesPrevious studies suggested a higher rate of COVID-19 infection in patients with multiple sclerosis than in the general population, and limited studies addressed the impact of COVID-19 and its vaccination in patients with multiple sclerosis in Iran. We decided to investigate the factors associated with COVID-19 infection, the effects and side effects of the COVID-19 vaccination in patients with multiple sclerosis (MS).MethodsWe used the data of the patients with multiple sclerosis registered in a referral clinic in Kerman, one of the large cities in Iran (a population of 537,000 inhabitants), to explore the association between demographic variables, the history of COVID-19 vaccination, and the clinical outcomes.ResultsOf the 367 participants in this study, 88.3% received the COVID-19 vaccine, 35.4% were confirmed COVID-19 cases, and the incidence of COVID-19 was much higher before vaccination (24.5% before vaccination versus 10.1% after vaccination). The multivariable logistic regression model showed that male gender (OR = 2.64, 95% confidence interval: 1.21, 5.74) and current employment (OR = 3.04, 95% confidence interval: 1.59, 5.80) were associated with an increased risk of COVID-19. The only factor associated with the adverse effects of COVID-19 vaccination was the type of vaccine (AstraZeneca).ConclusionOur findings showed that the vaccination protected MS cases considerably against COVID-19. In addition, the side effects of the vaccines were not noticeably high in these cases as well. Among all COVID-19 vaccines, AstraZeneca had the most common side effects, so people must be aware of them before vaccination. The male gender and employment were the most important variables in the prevalence of COVID-19 in patients with multiple sclerosis in our study.

In addition to its pulmonary effects, coronavirus disease 2019 (COVID-19) has also been found to cause acute kidney injury (AKI), which has been linked to high mortality rates. In this review, we collected data from 20 clinical studies on post-COVID-19-related AKI and 97 cases of AKI associated with COVID-19 vaccination. Acute tubular injury was by far the most common finding in the kidneys of patients with COVID-19-related AKI. Among patients hospitalized for COVID-19, 34.0% developed AKI, of which 59.0%, 19.1% and 21.9% were Stages 1, 2 and 3, respectively. Though kidney disease and other adverse effects after COVID-19 vaccination overall appear rare, case reports have accumulated suggesting that COVID-19 vaccination may be associated with a risk of subsequent kidney disease. Among the patients with post-vaccination AKI, the most common pathologic findings include crescentic glomerulonephritis (29.9%), acute tubular injury (23.7%), IgA nephropathy (18.6%), antineutrophil cytoplasmic autoantibody-associated vasculitis (17.5%), minimal change disease (17.5%) and thrombotic microangiopathy (10.3%). It is important to note that crescentic glomerulonephritis appears to be more prevalent in patients who have newly diagnosed renal involvement. The proportions of patients with AKI Stages 1, 2 and 3 after COVID-19 vaccination in case reports were 30.9%, 22.7% and 46.4%, respectively. In general, clinical cases of new-onset and recurrent nephropathy with AKI after COVID-19 vaccination have a positive prognosis. In this article, we also explore the underlying pathophysiological mechanisms of AKI associated with COVID-19 infection and its vaccination by describing key renal morphological and clinical features and prognostic findings.

This study assessed the incidence and severity of side effects associated with coronavirus disease 2019 (COVID-19) vaccination among healthcare workers registered with the Medical Council of the Islamic Republic of Iran. A retrospective cohort study was conducted on the healthcare workers focusing on the side-effects of COVID-19 vaccines from March to June 2021. Data were collected using online questionnaires. Multivariable logistic regression was used to assess the association between side effects of the vaccines and demographic variables, comorbidities, vaccine type, and history of COVID-19. Out of 42,018 people who were included, 55.85% reported at least one side effect after receiving the first vaccine dose. 4.59% of those with side effects sought diagnostic intervention or were referred to treatment centers. Multivariable logistic regression indicated that being a woman, higher education, having a history of COVID-19 infection, and having comorbidities increased the risk of side effects. The AstraZeneca vaccine significantly increased the risk of side effects compared to the Sputnik vaccine, while the Sinopharm vaccine decreased this risk. The risk of developing a side effect decreased with age. The risk of moderate and severe side effects was significantly associated with gender, younger age, comorbidities, and a history of COVID-19 infection. Moderate and severe side effects were less reported by those who received the Sinopharm vaccine. Clinical complications after COVID-19 vaccination, directly or indirectly caused by the vaccines, are common. However, the benefits of COVID-19 vaccines greatly outweigh the risk of reversible side effects, especially among the high-risk population.

COVID-19 (coronavirus disease 2019) vaccines have become available; now, everyone has the opportunity to get vaccinated. We used Google Trends (GT) data to assess the global public interest in COVID-19 vaccines during the pandemic. For the analysis, a period of 17 months was chosen (from Jan 19, 2020, to Jul 04, 2021). Interest in user queries was tracked by keywords (corona vaccine, COVID-19 vaccine development, Sputnik v, Pfizer vaccine, AstraZeneca vaccine, etc.). The geographic analysis of queries was also carried out. The interest of users in the vaccine is significantly increasing. It is focused on the side effects of vaccines, and users pay attention to vaccines’ developers from different countries. The correlation between the scientific publications devoted to vaccine development and such requests of users on the internet is absent. This study shows that internet search patterns can be used to gauge public attitudes towards coronavirus vaccination. Safety concerns consistently high follow an interest in vaccine side effects. This data can be used to track and predict attitudes towards vaccination of populations from COVID-19 in different countries before global vaccination becomes available to help mitigate the adverse effects of the pandemic.

Several COVID-19 vaccines have been implemented. However, some side effects of the vaccine have been reported, which are sometimes very harmful. Reported cases and data are still very limited regarding the psychiatric side effects of the COVID-19 vaccine. To our knowledge, only one case has been reported. In this paper, we report the case of a patient who presented an acute depressive episode 24 hours after receiving his first dose of the BNT162b2mRNA vaccine. The case was a 26-year-old man with a history of Down syndrome with moderately good autonomy for daily routine tasks. The patient, who presented hypothyroidism at 10 years old and schizophrenia at 15 years old, was doing well before the vaccination and received his first dose of the BNT162b2mRNA vaccine. Twenty-four hours later, he presented depressive symptoms that resolved spontaneously after one week. Then, fifteen days later, the symptoms reappeared, and the episode lasted for 5 weeks. The patient received 10 mg/day of escitalopram besides his usual treatment. The depressive symptoms improved considerably by the second day of treatment. The presented case illustrated significant diagnostic challenges, especially when taking into account the sequential relationship between the COVID-19 vaccine and the occurrence of depressive symptoms. A single case of depression has been reported after the administration of the COVID-19 vaccine. Scientific evidence suggests the important role of the immune system in the pathophysiology of various psychiatric disorders, including depression. Health professionals must take into consideration the potential psychiatric side effects even being rare so far, especially in vulnerable subjects. Further studies are required to establish the causal effects of depressive symptoms occurring during the weeks following the COVID-19 vaccine bolus injection.

Background & Aim: Hungary started to administer several COVID-19 vaccines; however, attitudes toward COVID-19 and vaccination are still poorly understood. This study aimed to explore how the attitudes toward COVID-19 disease are associated with the attitudes toward COVID-19 vaccination in Hungary and compare the attitudes of health and non-health workers toward COVID-19 disease and vaccination in Hungary. Methods & Materials: Using a descriptive, cross-sectional design, we recruited a sample of 1820 persons through an electronic survey. In addition to the sociodemographic questions, the attitudes towards COVID-19 disease and vaccination were assessed through self-developed, literature-based questionnaires. Principal component analysis, Spearman's correlation, linear regression, and the Mann-Whitney test were used in the data analysis. Results: The mean age for the study participants (n=1735) was 43.8 ± 6.2 years, and females were the majority (84.6%). Overall, participants showed good attitudes toward COVID-19 disease (mean score= 3.48, SD= 0.43) as compared to their attitudes toward COVID-19 vaccination (Mean score= 2.67, SD= 0.44). A positive correlation was found between the attitudes toward COVID-19 disease and attitudes toward vaccination in Hungary (r= 0.247, p< 0.01). Nurses and other health workers showed more positive attitudes toward COVID-19 vaccination than non-health workers. Conclusion: Hungarian decision-makers should intervene to improve the public's willingness to be vaccinated against COVID-19 or future pandemics. Health workers' knowledge and positive attitudes should be utilized in the media to encourage the general population to be vaccinated. The suggested questionnaires need to be validated for future pandemics' use.

Aims Despite various government measures, control of COVID-19 requires immediate action, including vaccine production. Given the role of vaccine acceptance factors in future planning, this study aimed to unfold the determinants of COVID-19 vaccine acceptance in Gonabad. Methods & Materials This descriptive-analytical study was performed on 292 people in Gonabad city, Iran, in 2021. The random multi-stage sampling method was used to select two groups of samples: Vaccinated and unvaccinated. The data collection tool consisted of a demographic checklist and a researcher-made questionnaire on the reasons for accepting or rejecting the COVID-19 vaccination. Data were collected by telephone and analyzed by SPSS software, version 23 using mean, standard deviation, and the Chi-square test at a significance level of less than 0.05. Findings Most of the research participants were women (51%). The Mean±SD age of the vaccinated and non-vaccinated groups was 57.55±12.24 and 55.38±41.1 years, respectively. Two factors of living with people at risk (88.5%) and respect for the rights of others (80.9%) were the most important reasons for accepting and worrying about the side effects of the vaccine (63%). Worrying about the content and lack of knowledge about the effectiveness of the vaccine (45.3%) were mentioned as the most important reasons for not accepting the COVID-19 vaccination. Conclusion Considering the importance of two factors, including the concern about the side effects of the COVID-19 vaccine and concern about the content and ineffectiveness of COVID-19 vaccine in rejecting COVID-19 vaccine, increasing public awareness and knowledge about the effectiveness of vaccines in the country seems necessary to plan and invest on a large scale in the country through reliable sources as well as efforts to reduce the fear of the consequences of vaccination.